drugset / Trial / NCT00840684

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

NCT00840684

Phase 1/2 Completed 135 enrolled Institut Paoli-Calmettes
Non-randomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as laromustine, daunorubicin, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of laromustine when given together with daunorubicin and cytarabine in treating patients with acute myeloid leukemia.

Timeline

Start
2009-01
Primary completion
2011-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject laromustine Other / unclassified Intravenous
Background Busulfan Small molecule
Background Cytarabine Small molecule Intravenous
Background Daunorubicin Small molecule Intravenous
Background Melphalan Small molecule
Background Mitoxantrone Small molecule
Background amsacrine Small molecule

Indications